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intermediate doses of radioactivity are suitable for these 
relatively slow-growing tumors (“long term low dose, not 
short term high dose concept”). After each 2 treatment 
cycles, restaging is performed by morphologic (CT/MRI) and 
molecular imaging (Ga-68 SSTR PET/CT), blood chemistry and 
tumor markers. All data are entered in a prospective 
structured database (over 250 items per patient).  
NET Center Bad Berka - Results 
Retrospective analysis was performed in 1000 patients (age 4 
- 85 years) with metastatic and / or progressive NETs, 
undergoing 1 - 9 cycles of PRRT at our center using Lu-177 
(n=331), Y-90 (n=170) or both (n=499). Median total 
administered activity was 17.5 GBq. Patients were followed 
up for up to 132 months after the 1st cycle of PRRT. Well-
differentiated NETs (G1-2) accounted for 54 %. Most patients 
(95.6 %) had undergone at least 1 previous therapy (surgery 
86.8 %, medical therapy 55 %, ablative therapy 14.2 % and 
radiotherapy 3.4 %). The median overall survival (OS) of all 
patients from the start of PRRT was 52 months (mo). Median 
OS according to radionuclide used: Y-90 24 mo, Lu-177 55 
mo, both (TANDEM or DUO PRRT) 64 mo; according to the 
grade of tumor: G1 87 mo, G2 55 mo, G3 28 mo, unknown 50 
mo; and according to origin of primary tumors: pancreas 45 
mo, small intestine 77 mo, unknown primary 55 mo, lung 36 
mo. Median progression-free survival (PFS) measured from 
the last therapy cycle was 22 mo, comparable for pancreatic 
(23 mo) and small intestinal (25 mo) NETs.The use of a 
combination of Lu-177 and Y-90 takes this heterogeneity into 
account. Sequential administration of Y-90 and Lu-177 
labeled analogues is useful for the treatment of larger 
tumors, followed by treatment of smaller metastases, 
respectively in further treatment cycles.ConclusionsPRRT 
lends a significant benefit in progression free survival as well 
as in overall survival in metastasized and / or progressive G1-
2 NETs as compared to other treatment modalities and 
regardless of previous therapies. Combination of Lu-177 and 
Y-90 (DUO) based PRRT may be more effective than either 
radionuclide alone. Up to 10 cycles of PRRT, given over 
several years were tolerated very well by most patients. 
Severe renal toxicity can be completely avoided or reduced 
by nephroprotection applying aminoacids; haematological 
toxicity is usually mild to moderate (except for MDS which 
occurs in approx. 3-5% of all patients treated). Quality of life 
can be significantly improved. PRRT should only be 
performed at specialized centers as NET patients need highly 
individualized interdisciplinary treatment and long term care. 
NETTER-1 is the first Phase III multicentric, randomized, 
controlled trial evaluating 177Lu-DOTA0-Tyr3-Octreotate 
(Lutathera®) in patients with inoperable, progressive, 
somatostatin receptor positive midgut NETs. 230 patients 
with Grade 1-2 metastatic midgut NETs were randomized to 
receive Lutathera 7.4 GBq every 8 weeks (x4 administrations) 
versus Octreotide LAR 60 mg every 4-weeks. The primary 
endpoint was PFS per RECIST 1.1 criteria, with objective 
tumor assessment performed by an independent reading 
center every 12 weeks. Secondary objectives included 
objective response rate, overall survival, toxicity, and 
health-related quality of life.Enrolment was completed in 
February 2015, with a target of 230 patients randomized 
(1:1) in 35 European and 15 sites in the United States. At the 
time of statistical analysis, the number of centrally 
confirmed disease progressions or deaths was 23 in the 
Lutathera group and 67 in the Octreotide LAR 60 mg group. 
The median PFS was not reached for Lutathera and was 8.4 
months with 60 mg Octreotide LAR [95% CI: 5.8-11.0 months], 
p<0.0001, with a hazard ratio of 0.21 [95% CI: 0.13-0.34]. 
Within the current evaluable patient dataset for tumor 
responses (n=201), the number of CR+PR was 18 (18%) in the 
Lutathera group and 3 (3.0%) in the Octreotide LAR 60 mg 
group (p=0.0008). Although the OS data are not mature 
enough for a definitive analysis, the number of deaths was 13 
in the Lutathera group and 22 in the Octreotide LAR 60 mg 
group (p=0.019 at interim analysis) which suggests an 
improvement in overall survival.The Phase III NETTER-1 trial 
provides evidence for a clinically meaningful and statistically 
significant increase in PFS and ORR, and also suggests a 
survival benefit in patients with advanced midgut NETs 
treated with Lutathera. 
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Radiation therapy is an integral component in the 
management of childhood CNS malignancies. Although high 
cure rates can be achieved, detrimental long term side 
effects often hamper the functional outcome.  
 
Technologies  
Stereotactic conformal radiation therapy, IMRT, 
tomotherapy, image-guided radiation therapy and proton 
therapy are increasingly used to provide an excellent 
coverage of the target. Multimodality imaging such as MRI, 
PET and spectroscopy are implemented in treatment planning 
and permit an exact definition and delineation of the target 
and organs at risk. Novel fractionation schedules exploit the 
radiobiological properties of tumour and normal tissue. The 
selection of treatment modality is based on the tendency of 
the tumour with respect to local infiltration and 
leptomeningeal spread. Craniospinal irradiation is the 
standard of care in medulloblastoma and metastatic germcell 
tumours. IMRT, tomotherapy and proton therapy provide a 
high conformality and excellent dose homogeneity 
throughout the target volume. Especially proton therapy has 
the ability to decrease the dose exposure to whole body and 
surrounding normal tissue thereby reducing the risk of acute 
and late effects. The major developments in radiation 
therapy of pediatric tumours are aimed to individually tailor 
radiation therapy to the target especially in irradiation of the 
tumours site such as ependymoma, low grade glioma. With 
the increasing complexity of irradiation techniques in the 
treatment of CNS malignancies formalised systems and 
comprehensive quality assurance programmes were 
introduced to provide an optimal and reproducible treatment 
on a high quality level. To reduce late effects RT parameters 
can be modified by the investigation of novel radiotherapy 
dose prescriptions and reducing dose exposure to 
neighbouring normal tissue with a maximal sparing of normal 
brain. The introduction of models to predict the impact of 
radiotherapy dose volume parameters on long-term 
neuropsychological function will help to further reduce the 
risk for late effects.  
 
Conclusion  
The rapid developments and small patient numbers as well as 
the lack of appropriate measurement instruments and 
difficult endpoints like quality of survival preclude the 
necessity to investigate the role of these new technologies 
within prospective randomised trials. Paediatric oncologists 
should therefore not refrain from including new technologies 
in their prospective trials as part of treatment standards. A 
detailed assessment of the long-term benefits and side 
effects is however necessary to define their precise role in 
the management of childhood CNS malignancies. 
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Image registration is the process of finding the 
transformation between two image sets. It is used widely in 
